SCHEMBL20072387

SCHEMBL20072387

CC(S)c1ccc(Cl)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ CXCR3 P49682 1/20 0.38
▸ MDM2 Q00987 1/20 0.38
▸ KCNH2 Q12809 2/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ PSEN1 P49768 2/20 0.37
▸ PSEN2 P49810 2/20 0.37
▸ APH1B Q8WW43 2/20 0.37
▸ NCSTN Q92542 2/20 0.37
▸ APH1A Q96BI3 2/20 0.37
▸ PSENEN Q9NZ42 2/20 0.37
▸ OPRM1 P35372 3/20 0.36
▸ S1PR3 Q99500 5/20 0.35
▸ S1PR1 P21453 3/20 0.35
▸ PDE2A O00408 2/20 0.35
▸ CYP3A4 P08684 2/20 0.33
▸ CYP3A5 P20815 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22303592 0.85 PSEN1 (0.41) LMNATP53HTTKCNH2PSEN1
SCHEMBL84107 0.83 LMNA (0.47) LMNATP53HTTCXCR3MDM2
SCHEMBL29618236 0.81 HTT (0.45) LMNATP53HTTCXCR3MDM2
SCHEMBL19816520 0.81 HTT (0.45) LMNATP53HTTCXCR3MDM2
SCHEMBL16046022 0.79 LMNA (0.64) LMNATP53HTTCXCR3MDM2
SCHEMBL8284264 0.79 LMNA (0.64) LMNATP53HTTCXCR3MDM2
SCHEMBL17215353 0.79 PDE2A (0.46) LMNATP53HTTCXCR3MDM2
SCHEMBL30399466 0.79 PDE2A (0.46) LMNATP53HTTCXCR3MDM2
SCHEMBL13778123 0.79 LMNA (0.64) LMNATP53HTTCXCR3MDM2
SCHEMBL17553254 0.79 LMNA (0.44) LMNATP53HTTCXCR3MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE CORPORATION 2023-02-09 — — US disclosed
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-01-18 — — US disclosed
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof PHGDH, PGD, PGK1 LMNA 3874/4885TP53 297/4885HTT 3947/4885
US-20180105508-A1 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF PHGDH, PGD, PGK1 LMNA 3829/4885TP53 245/4885HTT 4018/4885
US-20230043959-A1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS JAK1, JAK2, JAK3 LMNA 4686/4885TP53 1523/4885HTT 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback